Biochemistry · Nucleotide Metabolism and Disorders (Purine/Pyrimidine, Gout, Lesch-Nyhan, ADA-SCID)

Which pattern of regulation correctly describes human PRPP glutamyl amidotransferase, the committed enzyme of de novo purine synthesis?

  • A Inhibited only by the end product uric acid
  • B Activated by AMP and GMP, inhibited by PRPP
  • C Inhibited by AMP and GMP, activated by high PRPP
  • D Regulated solely by covalent phosphorylation by protein kinase A
Correct answer: C. Inhibited by AMP and GMP, activated by high PRPP

Explanation

PRPP glutamyl amidotransferase is feedback-inhibited by the purine end products AMP and GMP, acting synergistically at separate sites, and is driven forward when intracellular PRPP rises. Uric acid is a catabolic end product and does not regulate this enzyme. Covalent modification is not the regulatory mechanism here.

Reference: Harper's Illustrated Biochemistry, 32nd ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.

Sponsored

Want to test yourself?

Create a free account for timed mock tests, mistake tracking, and FSRS spaced-repetition revision across 43,000+ MCQs.

Start free → Log in

More Nucleotide Metabolism and Disorders (Purine/Pyrimidine, Gout, Lesch-Nyhan, ADA-SCID) MCQs

See all Nucleotide Metabolism and Disorders (Purine/Pyrimidine, Gout, Lesch-Nyhan, ADA-SCID) MCQs →